8-K - MiniMed Group, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

On March 18, 2026, MiniMed Group, Inc. announced U.S. FDA clearance for the MiniMed Flex, a next-generation smartphone-controlled insulin pump, several months ahead of schedule, enabling earlier commercialization of this key product. MiniMed expects to recognize a $157 million one-time charge in Q4 fiscal year 2026 related to minimum payments owed to Blackstone under their R&D funding agreement.

Key Takeaways

1FDA cleared MiniMed Flex insulin pump on March 18, 2026

2Clearance several months earlier than anticipated, facilitating earlier commercialization

3R&D funded in part by Blackstone Life Sciences Advisors L.L.C. affiliates

4Blackstone earns greater of mid-to-high single digit royalty on net sales or $157 million minimum for first two years post-approval and launch

5MiniMed to recognize $157 million one-time charge in Q4 FY2026

Current Report Details

Event Type

Regulation Fd

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

. Regulation FD Disclosure On March 18, 2026, MiniMed Group, Inc. (“MiniMed”) announced that the U.S. Food and Drug Administration (the “FDA”) has cleared the M

Regulation Fd

$157.0M$157.0M

Exhibits (1)

8-K

FORM 8-K